Embodiments of the present disclosure provide for arrays, systems, and methods analyzing cells, methods of making arrays, and the like.

A method involves recovery an extracellular vesicle from an extracellular vesicle-containing sample. Such a method of recovering the extracellular vesicle may include separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

A method involves recovery an extracellular vesicle from an extracellular vesicle-containing sample. Such a method of recovering the extracellular vesicle may include separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating cellular neurodamage or neurotrauma to the peripheral or central nervous system using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.

The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating cellular neurodamage or neurotrauma to the peripheral or central nervous system using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.

Novel anti-CD8 (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8 antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8 antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8 antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8 antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8 is detected or quantified in a sample.

Novel anti-CD8 (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8 antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8 antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8 antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8 antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8 is detected or quantified in a sample.

Novel anti-CD8 (cluster of differentiation 8 alpha) antibodies and antigen-binding fragments thereof, a fusion protein including the anti-CD8 antibodies and antigen-binding fragments thereof, and a nucleic acid molecule encoding the anti-CD8 antibodies and antigen-binding fragments thereof. Also, pharmaceutical compositions including the anti-CD8 antibodies and antigen-binding fragments thereof. Further, methods using the anti-CD8 antibodies and antigen-binding fragments thereof for treating CD8-related diseases and in vitro methods in which CD8a-expressing cells are depleted in a sample or in which CD8 is detected or quantified in a sample.

The present application provides methods of predicting the risk of a subject developing a xenograft rejection response, methods of monitoring the risk of a subject developing a xenograft rejection response, methods of identifying a new porcine antigen(s) recognized by anti-porcine antibodies, methods for creating a porcine xenograft donor with a minimized likelihood of inducing a xenograft rejection response, as well as reagents and kits suitable for use in the described methods.

The present application provides methods of predicting the risk of a subject developing a xenograft rejection response, methods of monitoring the risk of a subject developing a xenograft rejection response, methods of identifying a new porcine antigen(s) recognized by anti-porcine antibodies, methods for creating a porcine xenograft donor with a minimized likelihood of inducing a xenograft rejection response, as well as reagents and kits suitable for use in the described methods.